3 Agents to Watch for Decompensated Cirrhosis from NASH

HepaStem, BIV201, and Albutein are late-stage pipeline agents in development for NASH, focusing specifically on decompensated cirrhosis.

Related Keywords

United States ,America ,John Tchelingerian ,Sravani Meka ,Sandra Camprubi ,Promethera Group ,Acute On Chronic Liver Failure ,End Stage Liver Disease ,North America ,Announces Initiation ,Biovie Announces ,Patient Enrollment ,Ascites Phase ,Encouraging Efficacy Data ,Conduct Pivotal Registrational ,Long Term Administration ,Human Albumin ,Subjects With Decompensated Cirrhosis ,Study Record ,Nash ,Nonalcoholic Steatohepatitis ,Pipeline ,Hepastem ,Albutein ,Biv201 ,Cirrhosis ,Aclf ,Liver ,Ascites ,Decompensated Cirrhosis ,